The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus-Reference-Cited by-同舟云学术

The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus

Published:2013-08-20 Issue:3 Volume:76 Page:432-444
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Kasichayanula Sreeneeranj¹,Liu Xiaoni²,Pe Benito Melanie¹,Yao Ming³,Pfister Marc¹,LaCreta Frank P.¹,Humphreys William Griffith³,Boulton David W.¹

Affiliation:

1. Discovery Medicine and Clinical Pharmacology; Bristol-Myers Squibb Co; Princeton; NJ

2. Global Biometric Sciences; Bristol-Myers Squibb Co; Princeton; NJ

3. Pharmaceutical Candidate Optimization; Bristol-Myers Squibb Co; Princeton; NJ; USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.12056/fullpdf

Reference34 articles.

1. Diabetic nephropathy;Molitch;Diabetes Care,2003

2. Type II diabetes: a treatment approach for the older patient;Miller;Geriatrics,1996

3. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications;Bakris;Kidney Int,2009

4. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for d-glucose;Kanai;J Clin Invest,1994

5. Molecular analysis of the SGLT2 gene in patients with renal glucosuria;Santer;J Am Soc Nephrol,2003

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modeling Metformin and Dapagliflozin Pharmacokinetics in Chronic Kidney Disease;The AAPS Journal;2024-08-19

2. Dapagliflozin: A new hope for the therapeutic treatment of type 2 diabetes mellitus;European Journal of Medicinal Chemistry Reports;2024-08

3. The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium‐glucose cotransporter‐2 inhibitor, in type 2 diabetes;Diabetes, Obesity and Metabolism;2024-04-15

4. The SGLT2 inhibitor dapagliflozin improves kidney function in glycogen storage disease XI;Science Translational Medicine;2023-11

5. Effect of Astragali radix extract on pharmacokinetic behavior of dapagliflozin in healthy and type 2 diabetic rats;Frontiers in Pharmacology;2023-10-10